No Yes Ok

Archive

« Older Entries Newer Entries »

LSP leads a CHF 23 million Series C investment in Sequana Medical Monday, April 28th, 2014
Amsterdam, The Netherlands, 28 April 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the second investment of its Health Economics Fund (LSP HEF) in Sequana Medical AG, a priv [...]
AGENUS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH MERCK FOR NOVEL CHECKPOINT ANTIBODY-BASED CANCER IMMUNOTHERAPIES Monday, April 28th, 2014
• Agenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales   LEXINGTON, MA, April 28, 2014 —Agenus Inc. (NASDAQ: AGEN) announced today that t [...]
New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application Wednesday, April 23rd, 2014
Dutch study demonstrates excellent sensitivity of Unyvero™ cartridges   Holzgerlingen, Germany, April 23, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced posi [...]
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure Thursday, April 10th, 2014
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)   SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Celladon Corporati [...]
LSP proud sponsor of the Mediscience Awards 2014 Thursday, April 10th, 2014
Voting Deadline: May 9th   Shortlist announced: May 22nd   Awards dinner: June 19th   Nominations for the European Mediscience Awards 2014, of which LSP is a proud sponsor, are now open and [...]
Nexstim Selected as a 2014 Red Herring Top 100 Europe Wednesday, April 9th, 2014
The Only Medical Device Company Awarded   Helsinki, Finland (April 9, 2014) – Red Herring’s Top 100 Europe celebrates the exceptional accomplishments of technology companies and their position to grow at [...]
LSP’s steady hand Tuesday, April 8th, 2014
Published in BioCentury, March 31, 2014 When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months — early stage [...]
ARGEN-X USES ITS SIMPLE ANTIBODY™ PLATFORM TO IDENTIFY FOUR ‘HOTSPOTS’ ON MET AS TARGETS FOR ITS THERAPEUTIC ANTIBODY PROGRAM Monday, April 7th, 2014
New findings to be presented at the American Association for Cancer Research annual meeting   Breda, The Netherlands/Ghent, Belgium, 7 April 2014 – arGEN-X, a clinical stage human therapeutic antibody compa [...]
Hybrigenics launches Helixio, its new branch dedicated to genomic services Thursday, April 3rd, 2014
Paris, 03 April 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments against proliferative diseases a [...]
Hybrigenics successfully raised €6.1 million Wednesday, April 2nd, 2014
These funds will finance two new clinical Phase II studies of inecalcitol in acute myeloid leukemia and in chronic myeloid leukemia   Paris, 26 March 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical comp [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

LSP leads a CHF 23 million Series C investment in Sequana Medical Monday, April 28th, 2014
Amsterdam, The Netherlands, 28 April 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces the second investment of its Health Economics Fund (LSP HEF) in Sequana Medical AG, a priv [...]
AGENUS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH MERCK FOR NOVEL CHECKPOINT ANTIBODY-BASED CANCER IMMUNOTHERAPIES Monday, April 28th, 2014
• Agenus is eligible to receive ~$100 million in milestone payments as well as royalties on worldwide product sales   LEXINGTON, MA, April 28, 2014 —Agenus Inc. (NASDAQ: AGEN) announced today that t [...]
New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application Wednesday, April 23rd, 2014
Dutch study demonstrates excellent sensitivity of Unyvero™ cartridges   Holzgerlingen, Germany, April 23, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced posi [...]
Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure Thursday, April 10th, 2014
MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)   SAN DIEGO, April 10, 2014 (GLOBE NEWSWIRE) -- Celladon Corporati [...]
LSP proud sponsor of the Mediscience Awards 2014 Thursday, April 10th, 2014
Voting Deadline: May 9th   Shortlist announced: May 22nd   Awards dinner: June 19th   Nominations for the European Mediscience Awards 2014, of which LSP is a proud sponsor, are now open and [...]
Nexstim Selected as a 2014 Red Herring Top 100 Europe Wednesday, April 9th, 2014
The Only Medical Device Company Awarded   Helsinki, Finland (April 9, 2014) – Red Herring’s Top 100 Europe celebrates the exceptional accomplishments of technology companies and their position to grow at [...]
LSP’s steady hand Tuesday, April 8th, 2014
Published in BioCentury, March 31, 2014 When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months — early stage [...]
ARGEN-X USES ITS SIMPLE ANTIBODY™ PLATFORM TO IDENTIFY FOUR ‘HOTSPOTS’ ON MET AS TARGETS FOR ITS THERAPEUTIC ANTIBODY PROGRAM Monday, April 7th, 2014
New findings to be presented at the American Association for Cancer Research annual meeting   Breda, The Netherlands/Ghent, Belgium, 7 April 2014 – arGEN-X, a clinical stage human therapeutic antibody compa [...]
Hybrigenics launches Helixio, its new branch dedicated to genomic services Thursday, April 3rd, 2014
Paris, 03 April 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical group listed on the Alternext market of Euronext in Paris, with a focus on research and development of new treatments against proliferative diseases a [...]
Hybrigenics successfully raised €6.1 million Wednesday, April 2nd, 2014
These funds will finance two new clinical Phase II studies of inecalcitol in acute myeloid leukemia and in chronic myeloid leukemia   Paris, 26 March 2014 – Hybrigenics SA (ALHYG), a bio-pharmaceutical comp [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund